Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03731182 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT03731182 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 104 participants.
The verdict
NCT03731182, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study is designed to describe the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease.
Interventions
- BIOLOGICAL V114
- BIOLOGICAL Prevnar 13™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2020-06-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03731182
The ClinicalTrials.gov registry entry for NCT03731182 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which V114 is the first listed.
NCT03731182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03731182 about?
NCT03731182 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)". This study is designed to describe the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease.
What is the current status of trial NCT03731182?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2019-01-23. Estimated completion is 2020-06-08.
What interventions are being tested in trial NCT03731182?
The interventions under investigation include: V114 (BIOLOGICAL), Prevnar 13™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT03731182?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.